Brief: Tenax Therapeutics Announces Global License Amendment That Expands Rights To Levosimendan

Tenax Therapeutics

20/02/2024 13:42

Feb 20 (Reuters) - Tenax Therapeutics Inc  TENX.O :
    * TENAX THERAPEUTICS ANNOUNCES GLOBAL LICENSE AMENDMENT THAT
SIGNIFICANTLY EXPANDS RIGHTS TO LEVOSIMENDAN
    * AMENDMENT TO EXISTING AGREEMENT WITH ORION CORPORATION
EXPANDS
CO'S TERRITORY RIGHTS FROM NORTH AMERICA TO ENTIRE WORLD
    * TENAX THERAPEUTICS - MODIFIED MILESTONE PROVISIONS,
INCLUDING 
PAYMENT FOR REGULATORY APPROVAL IN JAPAN
    * : IMPROVED NET SALES ROYALTY RATE STRUCTURE, NOW RANGING
FROM
HIGH SINGLE-DIGIT TO LOW-TEEN PERCENTAGES
    * THROUGH AMENDMENT, TENAX GAINS GLOBAL DEVELOPMENT,
COMMERCIAL, &
IP RIGHTS FOR ORAL AND SUBCUTANEOUS FORMULATIONS IN PH-HFPEF

Source text for Eikon:  ID:nGNX60VJ7g 
Further company coverage:  TENX.O 

 ((Reuters.Briefs@thomsonreuters.com;))